Introduction: Meningiomas are one of the most common primary intracranial tumours. Although most meningiomas are benign, the spectrum also includes atypical and malignant meningiomas. Clinical outcome of meningiomas is often difficult to predict. The stratification of risk on the basis of histomorphology alone remains problematic; thus additional biomarkers are needed. In this study biomarkers of prognostic and therapeutic interest like Ki-67, p53 and HER2/neu have been studied in correlation with clinicopathological parameters. Materials and methods: A retrospective study on histologically diagnosed meningiomas was undertaken. Slides were retrieved and reviewed. Clinical details were recorded from the files in the archives of the department. Immunohistochemical staining with markers Ki-67, p53 and HER2/neu were performed and the findings were interpreted. Results: The study included 17 cases with an age range of 16 to 73 years and a male: female ratio of 1.1:1.There were 11 cases (64.7%) of primary tumours and 6 cases (35.3%) were recurrent tumours. WHO Grade I meningiomas were maximum and accounted for 70.5% followed by grade II (17.5%) and grade III (12%) meningiomas. Ki-67 expression was seen in all cases with progressively increased expression in higher grades. p53 expression was observed in all the cases with higher levels (>10%) in Grade II and Grade III meningiomas compared to grade I meningiomas. The HER2/neu staining was negative in all cases studied. Conclusion: Grade I meningiomas appear to have low mitotic count on morphology but have higher proliferation rate on Ki-67 studies. Most of the recurrent tumours have higher p53 expression (>10%). Hence, adjuvant studies with biomarkers Ki-67 and p53 will be helpful in precise grading of meningiomas.